Dengvaxia’s Restrictive Indication Will Make Immunization Recommendations Difficult, ACIP Members Say
Executive Summary
The need to screen individuals in dengue-endemic areas for prior infection before administering Sanofi’s vaccine will be difficult to operationalize, particularly in the absence of a reliable and rapid diagnostic, experts say; Advisory Committee on Immunization Practices working group aims for full committee vote on use recommendations in February 2020.
You may also be interested in...
Sanofi's Dengvaxia: ACIP Decision On Use Will Hinge On Screening Test
CDC advisory committee cannot recommend administration of Sanofi's dengue vaccine until there is an acceptable test to detect previous dengue infection and other questions are answered.
Merck & Co.’s Gardasil 9 Gets US CDC Panel Backing For Broader Age Group
Advisory Committee on Immunization Practices recommends vaccination based on shared clinical decision-making in individuals ages 27-45 years old – but says only those at high risk of contracting HPV are likely to benefit and should get the vaccine.
Keeping Track: US FDA Approves Sanofi’s Dengvaxia, But Heron’s HTX-011 And Nabriva’s Contepo Fall Short
The latest drug development news and highlights from our US FDA Performance Tracker.